课题基金 / 基金详情

GRANEXIN AS A TOPICAL THERAPEUTIC TO MITIGATE CUTANEOUS RADIATION INJURY

GRANEXIN AS A TOPICAL THERAPEUTIC TO MITIGATE CUTANEOUS RADIATION INJURY
GRANEXIN 作为减轻皮肤辐射损伤的局部治疗药物
批准号:
10589744
负责人:
GUATAM CHATNEKAR
金额:
$265.71万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-03-16 至 2023-03-15

项目摘要

项目成果

GUATAM CHATNEKAR的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Radiation Injury Description: Granexin® gel is an easy-to-use, stable, topically applied gel containing the short regulatory peptide (aCT1) that possesses potent anti-inflammatory properties and accelerates cutaneous wound healing. FirstString Research proposes to further validate the efficacy, safety, and therapeutic potential of Granexin in the mitigation and treatment of CRI. The proposed development efforts will support NDA submission to the FDA for Granexin as a medical countermeasure (MCM) for CRI under the Animal Rule.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GRANEXIN AS A TOPICAL THERAPEUTIC TO MITIGATE CUTANEOUS RADIATION INJURY
  • 批准号:
    10807956
  • 项目类别:
  • 资助金额:
    $213.19万
  • 财政年份:
    2021
  • 负责人:
    GUATAM CHATNEKAR
  • 依托单位:
海外基金